Table 1.

Literature review on PUK associated with other malignancies.

References	Age/gender	Underlying malignancy	Ocular outcome ocular medications	Systemic treatment
Morjaria et al. (11)	74-year-old male	Newly diagnosed acute myeloid leukemia (AML)	Bilateral PUK – CF* vision PO prednisolone G. dexamethasone 6/9 (RE**) and 6/12 (LE#) after 2 weeks	Chemotherapy
Chawla et al. (10)	24-year-old female	Newly diagnosed acute lymphocytic leukemia (ALL)	Right eye PUK, scleritis and bilateral optic nerve infiltration – PL∧ vision G. Prednisolone acetate 1% G. Gatifloxacin 0.3%, G. Homatropine still PL (BE) after 4 weeks due to optic atrophy	Chemotherapy
Malecha et al. (8)	75-year-old male	“Blast crisis” of known chronic myelomonocytic leukemia (CMML) diagnosed 3 years prior	Right eye PUK and Left anterior uveitis – 6/30 (RE) and 6/9 (LE) G. Prednisolone acetate 1% G. HomatropinImproved over 3 weeks	Hydroxyurea and allopurinol passed away from CMML complications 5 months later
Sainz de la Maza et al. (9)	68-year-old male	Newly diagnosed chronic myelogenous leukemia	Bilateral PUK – 6/60 (BE) Had recurrence of PUK and needed conjunctival recession, keratectomy and cyanoacrylate application 6/9 (RE) and 6/21 (LE) at 9 months with no recurrences	Cyclophosphamide, switched to Hydrea (had RE PUK recurrence after), then switched back to cyclophosphamide
	67-year-old female	Contiguous sebaceous cell carcinoma of the upper eyelid and superior temporal and inferior orbit	Left eye PUK – HM vision Had conjunctival recession, keratectomy and cyanoacrylate application Underwent left globe exenteration, no metastatic spread

PUK, peripheral ulcerative keratitis; CF, counting fingers.

^∧Perception to light, *counting fingers, **right eye, #left eye.